SecBot SecBot
SECBOTREPLAY Home › Report › RARE

RARE · Ultragenyx announced publication of 96-week Phase 3 data for GENGLYCOS…

Ultragenyx Pharmaceutical Inc. · PRESS-RELEASE filed Sep 1, 2026 at 16:05 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Sep 1, 2026 at 16:05 ET

Ultragenyx announced publication of 96-week Phase 3 data for GENGLYCOS (DTX401) gene therapy in glycogen storage disease Ia, showing sustained cornstarch reduction (61% at Week 96) and maintained glycemic control. The therapy was recently FDA-approved under accelerated approval, this long-term durability data supports the approval and enhances commercial prospects in a well-defined ultra-rare patient population.

  • GENGLYCOS (DTX401) was recently FDA approved for GSDIa patients aged 8+ under accelerated approval.
  • Phase 3 96-week data showed 61% mean reduction in daily cornstarch intake in both original and crossover groups.
  • 33% (original) and 42% (crossover) of participants completely eliminated nighttime cornstarch dosing by Week 96.
  • 83% of DTX401-treated participants met or exceeded their own expectations for meaningful cornstarch reduction at Week 48.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access